Prosecution Insights
Last updated: November 15, 2026

Staidson (Beijing) Biopharmaceuticals Co. Ltd.

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days

Analysis

Staidson (Beijing) Biopharmaceuticals Co. Ltd. is currently managing 1 pending office action. This active matter is being handled by 1 distinct examiner, EDGINGTONGIORDANO, FRANCESCA. The data shows that there are 0 distinct art units associated with this pending activity, which indicates a specific administrative placement for the application. With only 1 pending office action in the portfolio, the company's current prosecution efforts are entirely focused on this single interaction at the USPTO. The absence of a listed technology area suggests a unique or cross-disciplinary application.

EDGINGTONGIORDANO, FRANCESCA is the busiest examiner for the portfolio, currently overseeing 1 pending office action. For practitioners, this means that the immediate success of the portfolio depends on the specific requirements and feedback from this 1 distinct examiner. There are no other examiners or art units involved in the pending workload to provide a comparison or alternative path for patent acquisition. The presence of 0 distinct art units and 1 distinct examiner simplifies the tracking of the portfolio but places significant importance on the outcome of this 1 pending office action.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
0
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Multi-statute (no §101)1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
FISCHER, JOSEPH 1 43.4% +45.6%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18037503 LONG-ACTING NERVE GROWTH FACTOR POLYPEPTIDES AND USES THEREOF FISCHER, JOSEPH —

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18037503 LONG-ACTING NERVE GROWTH FACTOR POLYPEPTIDES AND USES THEREOF FISCHER, JOSEPH —

Top Art Units

Art UnitApps
1658 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18037503 LONG-ACTING NERVE GROWTH FACTOR POLYPEPTIDES AND USES THEREOF FISCHER, JOSEPH 1658 §103§112Other Final Rejection — Pending May 17, 2023

Managing Staidson (Beijing) Biopharmaceuticals Co. Ltd.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Staidson (Beijing) Biopharmaceuticals Co. Ltd. have?

Staidson (Beijing) Biopharmaceuticals Co. Ltd. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most Staidson (Beijing) Biopharmaceuticals Co. Ltd. applications?

Joseph Fischer has the most, with 1 of Staidson (Beijing) Biopharmaceuticals Co. Ltd.'s pending office actions.

What technology area are Staidson (Beijing) Biopharmaceuticals Co. Ltd.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month